India NewsHealth

AstraZeneca’s Covishield To Cause Rare Yet Serious Side Effects

A huge update for those who were a part of COVID vaccination programs! Rare side effects of the vaccination have surfaced, questioned by numerous health experts.

The Economic Times reported that AstraZeneca, the British-Swedish multinational pharmaceutical and biotechnology company, has legally acknowledged that its product, Covishield, can cause certain rare side effects.

AstraZeneca developed Covishield, which was produced by the Serum Institute of India. In India, Covishield was one of the primary vaccines provided to citizens.

AstraZeneca’s Statements

AstraZeneca is currently facing a lawsuit in a UK court. The lawsuit was filed after claims surfaced on the internet that AstraZeneca’s vaccine caused deaths. To date, 51 deaths have been reported, hence 51 cases have been filed against the company.

AstraZeneca finally admitted in one of the court papers that, “Covishield can, in very rare cases, cause TTS.” TTS stands for Thrombosis with Thrombocytopenia Syndrome.

Dr. Rajeev Jayadevan, a medical expert, told ANI,

“TTS is thrombosis with thrombocytopenia syndrome, which is basically a clot in the blood vessels of the brain or elsewhere, along with a low platelet count. It is known to occur in very rare instances following certain types of vaccines and also from other causes. According to the WHO, adenovirus vector vaccines, in particular, have rarely been associated with this condition.”

TTS: About, Diagnosis, Treatment

TTS, or Thrombosis with Thrombocytopenia Syndrome, is a serious yet rare health condition characterized by low platelet counts (thrombocytopenia) along with the formation of blood clots (thrombosis).

Various symptoms associated with TTS include neurological deficits, shortness of breath, leg swelling, abdominal pain, and severe headaches.

TTS can be diagnosed if blood tests are conducted to assess the levels of platelets in the blood. Moreover, to detect blood clots, imaging studies are required, reported the Times of India.

TTS can be treated with a multidisciplinary approach. It includes supportive care, anticoagulation therapy to prevent blood clotting, and hospitalization.

To manage and stabilize platelet levels in the body, plasma exchange and intravenous immunoglobulin (IVIG) can also be performed.

Patients with TTS are prone to severe complications like death and organ damage. Hence, close monitoring of patients by healthcare providers is a must.

Also Read: Online doctor consultations in India increase by 4 times after the Covid-19 pandemic: Report

Subhashree Panda

Subhashree Panda: A proficient content writer, editor, and researcher. With 4 years of experience and an MBA in finance, she crafts compelling narratives on global events. Her passion for diverse journalism genres resonates widely, fostering broad audience connections.

Related Articles